Literature DB >> 393777

Human immunity to group B streptococci measured by indirect immunofluorescence: correlation with protection in chick embryos.

L C Vogel, R R Kretschmer, K M Boyer, D M Padnos, C A Gadzala, S P Gotoff.   

Abstract

An indirect immunofluorescence (IF) assay has been developed as a useful semiquantitative method for determination of type-specific IgG antibody in human sera to the five serotypes of group B Streptococcus. Antibody titers measured by IF correlated with passive protection in chick embryos, and antibody titers associated with chick embryo protection were delineated. Except for types Ia and Ic, IF antibody to each of the streptococcal types was completely absorbed by homologous strains, and antibody titers were unchanged by incubation with heterologous bacteria. For types Ia and Ic, IF antibody was absorbed by either the Ia or the Ic strain and by native Ia carbohydrate antigen. Antibody titers measured by IF and chick embryo protection against types Ia and Ic were similar, but were divergent for Ib and Ic, a finding suggesting that antibody is predominantly directed to the major carbohydrate determinants. In addition, 29 of 31 sera that had been tested in chick embryos yielded comparable results in mice against challenge with type Ia group B Streptococcus, a finding further validating the chick embryo assay. Sera from all of 43 mothers of infants infected with group B streptococci had antibody titers by IF that were less than titers associated with protection in chick embryos.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 393777     DOI: 10.1093/infdis/140.5.682

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Passive protection by human sera in mice against challenge with strains of group B streptococci.

Authors:  Y Ichiman; K Yoshida
Journal:  Med Microbiol Immunol       Date:  1986       Impact factor: 3.402

2.  Immunoprophylaxis and immunotherapy of neonatal group B streptococcal infections.

Authors:  S P Gotoff
Journal:  Infection       Date:  1985       Impact factor: 3.553

3.  Immunoprophylaxis and immunotherapy of neonatal group B streptococcal infections.

Authors:  S P Gotoff
Journal:  Infection       Date:  1984 Mar-Apr       Impact factor: 3.553

4.  Enzyme-linked immunosorbent assay for measurement of antibody to type III group B streptococci.

Authors:  R A Polin; S D Douglas; D L Kasper; C J Baker
Journal:  J Clin Microbiol       Date:  1982-06       Impact factor: 5.948

5.  Antibody-independent classical pathway-mediated opsonophagocytosis of type Ia, group B streptococcus.

Authors:  C J Baker; M S Edwards; B J Webb; D L Kasper
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

6.  Protective levels of human immunoglobulin G antibody to group B streptococcus type Ib.

Authors:  K M Boyer; L S Kendall; C K Papierniak; M E Klegerman; S P Gotoff
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

7.  Class specificity of naturally acquired and vaccine-induced antibody to type III group B streptococcal capsular polysaccharide: determination with a radioimmunoprecipitin assay.

Authors:  M S Edwards; P A Fuselier; M A Rench; D L Kasper; C J Baker
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

8.  Type-specific protection of neonatal rats from lethal group B streptococcal infection by immune sera obtained from human volunteers vaccinated with type III-specific polysaccharide.

Authors:  B J De Cueninck; T K Eisenstein; T S McIntosh; G D Shockman; R M Swenson
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

Review 9.  Pathogenesis of neonatal group B streptococcal infections.

Authors:  R S Baltimore
Journal:  Yale J Biol Med       Date:  1982 May-Aug
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.